Break-Point: FDA Committee Votes To Restrict Quinolones, But Does Not Endorse Disability Syndrome
This article was originally published in RPM Report
Executive Summary
An FDA advisory committee review of quinolone antibiotic safety focused on a very old safety issue – but points to a new era in antibiotic development, and restricted use models.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
